Sign in
Active, not recruitingNo phase

Topical Oxygen Therapy for BRONJ

Key facts

Who runs it
Mansoura University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
36 people enrolled
Started
1 Apr 2026
Ended
Sept 2026
Type of study
Interventional, 2 groups
Treatments tested
  • Topical Blue®m application
  • PRF membrane placement
Record updated
24 July 2026

Who can take part

Age
18 years to 60 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (9)Hide the full registry criteria

Who can take part

  • Patient Age: ≥18 years
  • Patients diagnosed with BRONJ/MRONJ Stage 1-3 (AAOMS criteria).(25)
  • History of antiresorptive or antiangiogenic drug use
  • Patients willing to participate in the study's follow-up intervals and to provide informed consent

Who cannot take part

  • Previous radiotherapy to head and neck
  • Uncontrolled systemic disease (e.g., uncontrolled diabetes)
  • Known allergy to Blue®m components
  • Pregnancy or lactation
  • Uncooperative patients

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

A randomized clinical trial comparing Blue®m oral gel and autologous PRF membrane as adjuncts to surgical debridement in BRONJ/MRONJ patients.

The 2 groups in the trial

  • Study Group 1Treatment being tested

    18 patients diagnosed with BRONJ/MRONJ topical Blue®m oral gel were applied intraoperatively to the debrided bone surface and adjacent soft tissues before primary closure.

    Treatment: Topical Blue®m application

  • Study Group 2Treatment being tested

    18 patients diagnosed with BRONJ/MRONJ autologous PRF membrane was prepared intraoperatively and placed over the debrided bone surface prior to flap closure.

    Treatment: PRF membrane placement

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy of Topically Applied Oxygen-Based Therapy Versus Platelet-Rich Fibrin for Medication-Related Osteonecrosis of the Jaws: A Randomized Controlled Trial
Record updated
24 July 2026